Studies Show Pomegranate Supplement Slows Neurodegenerative Diseases

By News

Article link- Studies Show Pomegranate Supplement Slows Neurodegenerative Diseases

Publication (pdf)- Delay of gCJD aggravation in sick TgMHu2ME199K mice by combining NPC transplantation and Nano-PSO administration    by Kati Frida, Orli Binyamina, Areen Usmana, Ruth Gabizona, Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, Jerusalem, Israel b Medical School, The Hebrew University, Jerusalem, Israel

Information provided by Professor Ruth Gabizon from Israel and studies into Pomegranate Seed Oil (PSO) marketed as Granagard.

LAY SUMMARY  of the publication:

Granagard is a nano formulation of PSO (pomegranate seed oil). PSO comprises 80-90% of Punicic Acid (omega 5) which is the strongest natural lipid antioxidant. In vivo, Punicic acid metabolizes into a specific form of conjugated linoleic acid (CLA), which is known to be a calpain inhibitor, suggested as a treatment target for several neurodegenerative conditions. While the active components, both PSO and CLA, do not enter the brain following administration of PSO and actually also CLA, following administration of the Granagard formulation, CLA is found in the brain of rodents, concomitantly with its neuroprotective effect that cannot be found when natural PSO was administrated. Most of our prion related experiments were done in a genetic model of E200K CJD. These mice are born heathy, then start to show neurological disabilities at 5-6 month of age and from there deteriorate until a terminal state at about 12 months of age. They mimic the situation of healthy carriers since they present spontaneous disease caused by a mutant PrP. Continuous Granagard administration from birth or 3 months of age delays the presentation of terminal disease in these mice by almost 6 months. The mechanism of activity of Granagard is most probably related to the maintenance of normal mitochondrial activity even under the stress caused by abnormal protein aggregates, thereby allowing neuronal survival under disease. This is applicable to a number of neurodegenerative disease diseases as well as normal aging.

Several human studies are in process (Alzheimer’s disease (AD) ,Parkinson’s disease (PD). Preliminary results in a double-blind study shows that administration of Granagard as compared to placebo improves memory and cognition in MS patients under diverse treatments. As for CJD, we are mostly interested in delay/prevention in asymptomatic carriers of pathological PrP mutations. It is indeed very difficult to establish a proper clinical study to establish if carriers taking Granagard will get sick later or never as compared to those taking placebo. Nobody wants to be in the placebo group for years and most people don’t want to get tested for the mutation. Therefore, we are looking at this in a different manner. Since Granagard is a safe food supplement beneficial to the general public, we follow a large group of genetic families in Israel in which all/most the siblings in affected families are taking it. Then we look, with the help of the medical community in Israel, at the new CJD patients. We believe 30-50% of CJD affected families are taking Granagard regularly.

We have learned so far that
1: No symptomatic CJD patient has taken Granagard prior to diagnosis.
2: The general number of genetic CJD patients, which was around 20 per year for several years until 2017, has gone down to less than 10 in 2018/2019 and may be as low in 2020.

Obviously, this is all observational and more time is needed to establish if we had affected disease onset, but it looks very encouraging.

Book release: ‘Creutzfeldt-Jakob disease. One case in a million’

By News

When illness enters a person’s life, it does not ring the bell, it does not knock on the door, it does not ask for permission. It just comes in. It is silent and discreet, but then suddenly it explodes, devastates, destroys and pulverises everything it encounters on its way.

Maria Gabriella lost her dad to CJD disease.

Her story and experience of the disease first became a graduation thesis that Maria Gabriella presented a few years ago at an AIEnP meeting dedicated to family members and which today has become a testimony book of dad’s illness experienced and seen through the eyes of a daughter, and the consequences that have affected and marked her family.

Maria Gabriella is a strong woman, with an enormous inner strength. Writing her story has has helped her to overcome the pain that affected her.


Creutzfeldt-Jakob disease. One case in a million
Author: Maria Gabriella Schirinzi
Publisher: Youcanprint
Pages: 132
Cover: soft
ISBN: 9788831659109
Version: English

Price: €17 plus shipping


PRNP Guidelines now published by Human Genetics Society of Australasia

By News

These guidelines have been developed by a committee consisting of representatives of clinical genetic services, genetic testing laboratories, the CJD Support Group Network (CJDSGN) and the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). Feedback and information from the New Zealand CJD Register, Human Genetics Society of Australasia and Genetic Services is incorporated.

2019 PS03_Guidelines for PRNP genetic testing

CJDSGN Meeting- Brisbane

By Events, Meetings, News

You are invited to attend a CJD Support Group Network (CJDSGN) meeting.

  • Date: Saturday 1st February, 2020
  • Time:  2pm to 5.30pm – afternoon tea will be provided
  • VenueSoda Apartments
  • Address: 27 Cordelia Street, South Brisbane
  • Telephone No: 07 3844 9988
  • RSVP: Thursday 30th January, 2020. Final numbers will be required for catering purposes by this date.
  • email: or call the toll free number 1800 052466
  • Hosted by:  Suzanne Solvyns and David Ralston – and members of the Committee of the CJD Support Group Network. 

This meeting is an informal meeting where you will have the opportunity to ask any questions, share your stories and link in with others for mutual support.

We will also be providing an update on project designed to assist ‘at risk of CJD’ individuals and CJD patients and their families.

This is also a great opportunity to get some feedback from the 12th annual national CJD conference if you were unable to attend.

The 1800 052466 will be diverted to my mobile in case you need to make contact on the day of the meeting. 

Dr Cathryn Haigh

By News

So proud of Dr Cathryn Haigh, affectionately known as ‘Our Cath’ as she worked with our researchers in Australia for many years before becoming a senior researcher at the Rocky Mountain Laboratories in Hamilton, USA.

Cath contributes the start of this work to a donation made via the CJDSGN as seed money by Mr Graham Murray of AACS Pty Ltd in memory of his daughter Silva Coelho who died of CJD at age 39 in 2009.

Graham has also funded a number of grants and memorial awards as well as travel award that assist students and young researchers to attend International Prion conference.

The CJDSGN is very proud and grateful of the support that families provide from their fundraising efforts and memorial donations enabling the CJDSGN to assist our researchers so far by providing 1.2 million in funding support.

We certainly are a CJD family community working together towards a treatment or cure.

Registration Now Open- 11th Annual National CJD Conference

By Events, News, Presentations

CJD Support Group Network’s 11th Annual National CJD Conference

Registration is now open for the 11th Annual National CJD Conference. 

Join us to honour 25 years of support and surveillance in Australia.


– TO BOOK TICKETS VIA EMAIL/MAIL/PHONE : CJD_Conference 2018_Registration Form 


Please join us for a day of bonding, awareness and knowledge!

A conference on Creutzfeldt-Jakob disease (CJD) and other prion diseases for:

  • CJD family members
  • People at increased risk of developing CJD
  • Health care professionals involved in patient care or infection prevention and control.

For CJD family members this is an opportunity to meet with other family members, share your stories, get answers to those outstanding questions from world experts, nd out what research is happening and how you can help by raising funds, promoting awareness and educating your local health care professionals.

For those at increased risk of developing CJD an update on iatrogenic (medically acquired CJD) and expert advice on how the CJD infection control guidelines affect you.

For health care professionals this is an opportunity to learn more about CJD and prion disease or help by sharing your knowledge and experience. We need champions who help promote awareness and knowledge and those of you who attend our conference are our champions.

Friday 23rd November, 2018 – Meeting for Genetic CJD family members.
Saturday 24th November, 2018 – All day meeting for CJD families, people at increased risk of developing CJD and Health Care Professionals involved in patient care or infection prevention and control.

Key Note SpeakerProfessor Richard Knight, Professor of Clinical Neurology, University of Edinburgh and UK National CJD Surveillance Unit.

  • Free for those at risk and CJD family members.
  • Registration for Health Care Professionals – $60 for the full day.
  • Location- Jasper Hotel, Melbourne